Four states dropped coverage in late 2025: California, New Hampshire, Pennsylvania , and South Carolina all eliminated Medicaid coverage of GLP-1s for obesity treatment reducing the national count from 16 states to 13
Atherosclerotic arteries become less efficient at delivering blood, increasing the risk of heart attack, stroke, and peripheral arterial disease
But they rarely explain how to choose that day strategically
Men typically lose slightly faster in absolute pounds due to higher starting weights and muscle mass
When Novo Nordisk faced production issues, choosing Eli Lilly's Mounjaro and Zepbound over Novo Nordisk's Wagovy became easier
[13] [14] UK SmPCs for licensed GLP-1 receptor agonists do not list medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) as formal contraindications, but advise vigilance for symptoms such as a neck lump, hoarseness, or difficulty swallowing